There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report), Elevance Health (ELV – Research Report) and Abbott Labs (ABT – Research Report) with bullish sentiments.
SAB Biotherapeutics (SABS)
H.C. Wainwright analyst Edward White reiterated a Buy rating on SAB Biotherapeutics today and set a price target of $2.00. The company’s shares closed last Thursday at $0.75.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on SAB Biotherapeutics is a Moderate Buy with an average price target of $2.50, implying a 262.3% upside from current levels. In a report issued on October 6, Chardan Capital also maintained a Buy rating on the stock with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
Elevance Health (ELV)
RBC Capital analyst Ben Hendrix reiterated a Buy rating on Elevance Health today and set a price target of $572.00. The company’s shares closed last Thursday at $468.81.
According to TipRanks.com, Hendrix is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elevance Health with a $582.10 average price target, which is a 24.3% upside from current levels. In a report issued on October 16, Bernstein also maintained a Buy rating on the stock with a $629.00 price target.
Abbott Labs (ABT)
RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Abbott Labs yesterday and set a price target of $119.00. The company’s shares closed last Thursday at $95.48.
According to TipRanks.com, Chadha is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Abbott Labs has an analyst consensus of Moderate Buy, with a price target consensus of $118.38, which is a 22.6% upside from current levels. In a report issued on October 16, UBS also maintained a Buy rating on the stock with a $118.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SABS:
- SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
- SAB Biotherapeutics downgraded to Neutral from Buy at Ladenburg
- SAB Biotherapeutics approves appointment of Moin to board of directors
- SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
- SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
